Home › Funds › IRIDIAN ASSET MANAGEMENT LLC/CT › TGTX
IRIDIAN ASSET MANAGEMENT LLC/CT position in TGTX
TG THERAPEUTICS INC · Health Care
IRIDIAN ASSET MANAGEMENT LLC/CT reported holding 27,689 shares of TGTX (TG THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.56% of its reported portfolio and ranking #35 among its reported holdings. IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed TGTX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How IRIDIAN ASSET MANAGEMENT LLC/CT's TGTX position evolved
IRIDIAN ASSET MANAGEMENT LLC/CT first disclosed a stake in TGTX in Q2 2024 at 39,357 shares (US$700K). The position peaked in Q3 2025 at 75,289 shares, worth US$2.7M. Across 10 filings, IRIDIAN ASSET MANAGEMENT LLC/CT increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 27,689 shares valued at US$1.5M. Notable position changes include a 58% increase in Q3 2025 (shares fell 17% over the following quarter), a 63% trim in Q2 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 39.36K | $700.16K | New |
| Q3 2024 | 47.53K | $1.11M | Add |
| Q4 2024 | 47.53K | $1.43M | Hold |
| Q1 2025 | 47.53K | $1.87M | Hold |
| Q2 2025 | 47.53K | $1.71M | Hold |
| Q3 2025 | 75.29K | $2.72M | Add |
| Q4 2025 | 75.29K | $2.24M | Hold |
| Q1 2026 | 75.29K | $2.50M | Hold |
| Q2 2026 | 27.69K | $1.52M | Reduce |
| Q3 2026 | 27.69K | $1.54M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TGTX and 13F data
TGTX (TG THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in TGTX — the largest reported positions include Soleus Capital Management, L.P. (US$160.9M), CONGRESS ASSET MANAGEMENT CO (US$145.4M), Opaleye Management Inc. (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TGTX
- Soleus Capital Management, L.P. 2.93M sh · $160.86M · Q2 2026
- CONGRESS ASSET MANAGEMENT CO 2.61M sh · $145.39M · Q3 2026
- Opaleye Management Inc. 535.00K sh · $29.39M · Q2 2026
- Penn Capital Management Company, LLC 480.88K sh · $26.88M · Q3 2026
- Occam Crest Management LP 425.00K sh · $22.73M · Q2 2026
- 683 Capital Management, LLC 389.08K sh · $21.38M · Q2 2026
More on IRIDIAN ASSET MANAGEMENT LLC/CT
FAQ
How long has IRIDIAN ASSET MANAGEMENT LLC/CT held TGTX?
IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed TGTX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is IRIDIAN ASSET MANAGEMENT LLC/CT's current position in TGTX?
As of Q3 2026, IRIDIAN ASSET MANAGEMENT LLC/CT holds 27.69K shares of TGTX (TG THERAPEUTICS INC), valued at $1.54M, representing 0.56% of its reported portfolio and ranking #35.
Has IRIDIAN ASSET MANAGEMENT LLC/CT been buying or selling TGTX?
In the latest 13F filing (Q3 2026), IRIDIAN ASSET MANAGEMENT LLC/CT held unchanged its position in TGTX. The position peaked in Q3 2025 at 75.29K shares.
Which other funds hold TGTX?
Other major institutional holders of TGTX include Soleus Capital Management, L.P., CONGRESS ASSET MANAGEMENT CO, Opaleye Management Inc., among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.